All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On February 1, 2021, it was announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) provided a positive opinion for the extended approval of pembrolizumab as monotherapy for certain patients with relapse/refractory (R/R) classical Hodgkin lymphoma (cHL). The recommendation is for adult and pediatric patients ≥ 3 years of age who have failed autologous stem cell transplant (auto-SCT) or received ≥ 2 prior therapies when auto-SCT is not a treatment option.1
This recommendation was based on results of the phase III KEYNOTE‑204 trial (NCT02684292) previously discussed by John Kuruvilla at the American Society of Clinical Oncology (ASCO) 2020 meeting, which showed a significant improvement in progression-free survival for patients treated with pembrolizumab compared with brentuximab vedotin (BV; 13.2 months vs 8.3 months). The recommendation was also based on supportive data from an updated analysis of the phase II KEYNOTE‑087 trial (NCT02453594), previously reported on the Lymphoma Hub. This analysis showed pembrolizumab to have durable responses, and a manageable safety profile in adult patients with R/R cHL who failed auto-SCT and BV or who were transplant ineligible and failed BV. This trial led to the approval of pembrolizumab in this subset of patients by the EMA.1
If approved, this will be the first pediatric indication for pembrolizumab in Europe. A final decision by the European Commission is expected in the first quarter of 2021.1
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox